Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis

BACKGROUND: Lymphangioleiomyomatosis is a rare disease caused by unregulated activation of mammalian target of rapamycin (mTOR) signalling pathway. Sirolimus showed efficacy in a phase 3 trial of patients with lymphangioleiomyomatosis, but the optimal dose remains unclear. METHODS: We investigated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Hee-Young, Hwang, Jung Jin, Kim, Dong Soon, Song, Jin Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236936/
https://www.ncbi.nlm.nih.gov/pubmed/30428897
http://dx.doi.org/10.1186/s13023-018-0946-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236936/
https://www.ncbi.nlm.nih.gov/pubmed/30428897
http://dx.doi.org/10.1186/s13023-018-0946-8

Ejemplares similares